ALLO vs GLD
Allogene Therapeutics Inc (ALLO) versus SPDR® Gold Shares (GLD) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
SPDR® Gold Shares (GLD) common stock listed on NYSE ARCA.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
GLD does not have a complete income-statement cache yet.
ALLO currently screens at market cap $258.1M. GLD currently screens at market cap $0.
Not investment advice. Open the ALLO and GLD stock pages for the full models.
Not investment advice.